Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 12Colorectal Neoplasms 9Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Pancreatic Neoplasms 3Colonic Neoplasms 3Skin Neoplasms 2Skin Diseases 2Rectal Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumor 1Soft Tissue Neoplasms 1Recurrence 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Imatinib Mesylate 41Sunitinib 17nilotinib 12regorafenib 10ripretinib 6avapritinib 6Leucovorin 3Ipilimumab 3Gemcitabine 3Dasatinib 3CTLA-4 Antigen 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2Paclitaxel 2Oxaliplatin 2Midazolam 2Irinotecan 2Fluorouracil 2Floxuridine 2Erlotinib Hydrochloride 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2Biopsy, Fine-Needle 2Bevacizumab 2vatalanib 1umbralisib 1trametinib 1tinostamustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Stromal Tumors × binimetinib × Clear all
NCT03158103 2021-04-30

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
3 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡